IMMUNEEL THERAPEUTICS PRIVATE LIMITED

IMMUNEEL THERAPEUTICS PRIVATE LIMITED is an Indian biotechnology company based in Bengaluru. It is dedicated to developing innovative and accessible cell and gene therapies, primarily focusing on advanced Chimeric Antigen Receptor (CAR) T-cell therapies for oncology (cancer) patients. The company's mission is to make these complex and cutting-edge treatments affordable and available, particularly in India and other low- and middle-income countries.

Immuneel Therapeutics is a clinical-stage company, meaning it is actively involved in the research, development, and clinical trials of its therapeutic candidates, rather than having commercially launched products on the market yet. They aim to address the unmet medical needs in cancer treatment through their indigenous cell therapy platforms.

IMMUNEEL THERAPEUTICS PRIVATE LIMITED is a developer and manufacturer of advanced cell and gene therapies. They are not a trading company. They establish and operate Good Manufacturing Practice (GMP) compliant facilities for the highly specialized production of their patient-specific cellular therapies for clinical trials and eventual commercialization. This indicates their involvement in the direct creation and processing of their therapeutic products.

Here are the products manufactured or marketed by IMMUNEEL THERAPEUTICS PRIVATE LIMITED, presented directly:

* CAR-T cell therapy (for cancer treatment)

* IMN-007A (CD19 targeted CAR-T cell therapy)

* Other cell-based immunotherapies